Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.

Royalty Pharma

Deerfield

Red Abbey Venture Partners

Federated Kaufmann Fund

International BM Biomedicine Holdings AG

New Medical Technologies

Duke University

Sevin Rosen Funds

Mayfield Fund

Vulcan

Cytokinetics

CYTK Investors: Today we announced we will be presenting at the upcoming Oppenheimer & Co. Inc. investor conference on February 13, 2024. 

Today we recognize #WearRedDay to spread awareness for women's heart health. Cardiovascular disease is the leading cause of death for women, killing more women than all forms of cancer combined and impacting women of all ages. Yet, many women don’t know that heart disease is their number one killer, made even worse by the fact that certain heart diseases can be “silent” or not diagnosed. Together, by wearing red, we are showing our support for heart disease prevention and bringing attention to the importance of heart health. #HeartMonth #HeartDiseaseAwareness #OurHearts #GoRedForWomen

To celebrate #BlackHistoryMonth, we're honoring the rich tapestry of African American culture and heritage that has shaped our world. This month is not just about the past, it's a call to action for the present and future. Let's learn, engage and uplift one another as we continue to build a world that celebrates diversity.

Learn more about the significance of this annual observance: https://bit.ly/3gptsgl

February is #HeartMonth! Follow along as we talk about #HeartDisease and connect with the community. Throughout the month, we will also be hosting internal company events to raise awareness and learn from patients about the burden of living with heart disease. #HCM

Today we announced the recipients of our sixth annual Cytokinetics Communications Grant Program. We are proud to support advocacy organizations in their efforts to build awareness and community engagement. 

Learn more:

IPhone / Mobile Compatible

Viewport Meta

Google Tag Manager

Apple Mobile Web Clips Icon

DNSSEC

Google Maps

WordPress

Amazon

IPv6

Sitelinks Search Box

EVP, Chief Commercial Officer

Andrew Callos

Independent Consultant in Clinical Research and Development

Andrew Wolff

Senior Vice President Regulatory and Compliance

Bonnie Charpentier

Executive Vice President, Research and Development

Fady Malik

Vice President, Marketing

Jennifer Laux

Vp, CMC

Norma Tom

Associate Director, Clinical Bioanalysis

Adrienne Griffith

Senior Director Finance - R&D and Commercial Supply Chain

Al Pan

Business Management

Alec Brozell

Director, Tech Ops CMC Analytical

Amy Wang

James Sabry

B. Lynne Parshall

Michael Schmertzler

Steve Dow

Daniel Ramos

Recruiter

Robert Blum

President & CEO

Ronald Vale

Co-Founder, Cytokinetics; Professor and Howard Hughes Investigator

Patrick Gage

Chairman of the Board of Directors

David Morgans

Consultant

Sung Lee

Health Care Companies With More Than 10 Employees (Top 10K)

Harvard University Alumni Founded Companies

San Francisco Bay Area Companies With More Than 50 Employees (Top 10K)

Health Care Companies that Exited (Top 10K)

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

Post-IPO Equity - Cytokinetics

Post-IPO Debt - Cytokinetics

Series E - Cytokinetics

South San Francisco

California

United States

North America

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Announces Data From Phase 1 Study of CK-4021586

ESC-ape velocity? Cytokinetics revs HCM case with aficamten

A cardiac myosin activator being evaluated for its potential to improve heart function in patients with heart failure with reduced ejection fraction.

A cardiac myosin inhibitor under investigation for the treatment of hypertrophic cardiomyopathy, aiming to reduce heart muscle thickening.

A fast skeletal muscle troponin activator designed to improve muscle function and exercise tolerance in conditions like heart failure.

Cytokinetics conducts clinical trials to assess the safety and efficacy of its investigational drugs for cardiovascular and neuromuscular diseases.

Malta

Europe

United Kingdom

India

Asia

Croatia

HTML5

GreenSock Animation Platform

Bootstrap

Wordpress

Google Analytics

Microsoft Outlook

Google Fonts

jQuery

Cloudflare CDN

Maze Therapeutics is a biotechnology company focused on developing therapies for genetic diseases.

Maze Therapeutics

Cytori Therapeutics is a biotechnology company specializing in regenerative medicine and developing cell-based therapeutics.

Cytori Therapeutics

Assembly Biosciences is a biotechnology company focused on developing innovative treatments for hepatitis B virus and other viral infections.

Assembly Biosciences

Amylyx Pharmaceuticals is a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases.

Amylyx Pharmaceuticals

Orphazyme is a biopharmaceutical company focused on developing therapies for rare neurodegenerative diseases.

Orphazyme

MediciNova is a biopharmaceutical company engaged in developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs.

MediciNova

Spider Biotech is a biotechnology company focused on developing synthetic peptide therapeutics for innate immunity and antimicrobial defense.

Spider Biotech

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases affecting muscle performance.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

news impact assignment basic	general	Mar 5, 2024 1:25 AM	4d2acf7a
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 1:25 AM	5fda2fa9
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	fdc2b0dc
crunchbase profile	general	Nov 19, 2024 11:26 AM	e01e6a29
li profile	general	Mar 5, 2024 1:25 AM	f5f0cf97
translate crunchbase fundingrounds	general	Nov 19, 2024 1:28 PM	b514ef5a
peers	general
news basic	general	Mar 5, 2024 1:25 AM	30ee60d3
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CYTOKINETICS

Cytokinetics, Incorporated

Last Close

47.67

22/11 21:00

Market Cap

6.30B

Beta: -

Volume Today

1.44M

Avg: -